MRNA
Moderna Inc
194.80$
+7.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 55.5% | 56.0% | 57.4% | 61.6% | 61.2% | 57.3% | 53.3% | 51.4% | 54.4% | 53.0% | 50.2% | 53.1% | |
| 15.1% | 15.8% | 12.3% | 15.8% | 10.4% | 13.6% | 12.8% | 10.6% | 9.3% | 21.0% | 16.6% | 15.7% | |
| 38.9% | 46.7% | 50.9% | 54.1% | 43.5% | 49.7% | 47.0% | 42.7% | 37.1% | 47.0% | 45.3% | 46.9% | |
| 11.0% | 5.9% | 2.3% | 2.7% | 11.6% | 4.2% | 2.4% | 3.8% | 11.5% | 2.3% | 1.3% | 0.9% | |
| 2.5% | 1.1% | 1.8% | 2.5% | 2.6% | 0.8% | 1.0% | 2.0% | 2.7% | 1.2% | 1.3% | 2.6% | |
| 14.0% | – | – | – | – | – | – | – | – | – | – | – | |
| 0.3% | 0.3% | 0.3% | 0.3% | 0.3% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.5% | 0.5% | |
| 0.2% | 0.2% | 0.3% | 0.3% | 0.3% | 0.3% | 0.4% | 0.4% | 0.4% | 0.4% | 1.0% | 1.0% | |
| 30.8% | 24.8% | 23.4% | 25.3% | 24.5% | 22.9% | 20.8% | 21.7% | 23.1% | 29.9% | 35.5% | 38.3% | |
| 22.5% | 16.4% | 14.2% | 15.1% | 13.9% | 15.6% | 12.6% | 13.1% | 13.9% | 16.1% | 20.8% | 23.1% | |
| 0.9% | 0.1% | 0.1% | 0.2% | 0.3% | 0.3% | 0.3% | 0.4% | 0.4% | – | 0.4% | 0.5% | |
| 2.5% | 2.8% | 1.1% | 1.8% | 2.4% | 2.9% | 1.8% | 1.5% | 2.2% | 2.6% | 1.4% | 1.5% | |
| – | – | – | – | – | – | – | – | – | 4.8% | 5.1% | 5.4% | |
| 69.2% | 75.2% | 76.6% | 74.7% | 75.5% | 77.1% | 79.2% | 78.3% | 76.9% | 70.1% | 64.5% | 61.7% | |
| 68.8% | 73.8% | 74.3% | 71.1% | 70.7% | 71.0% | 71.4% | 68.7% | 66.3% | 58.5% | 51.2% | 46.5% | |
| 2.0% | 2.1% | 2.3% | 2.4% | 2.5% | 2.7% | 3.0% | 3.2% | 3.2% | 3.2% | 3.4% | 3.6% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.